Live Investor briefing, page-38

My random ignorant ramblings on this...

Seems like PTX200 is in a crowded field and probably not a high enough efficacy/safety at the doses required to make it stand out from the pack, nor make it commercially viable.
I am not sure what deal they will make with a 3rd party, but I've got the feeling that those costs are mostly a write-off. Why would anyone take it on in this climate and with the whole landscape changing so fast??.
The one positive outcome seems that is has potential as "CellPryme".

For PTX100, It's great to see positive outcomes, though for all the bravado it never struck me as something that would be particularly lucrative. I've got no idea how to value it, but the numbers for Folotyn are not mind blowing. If they got $300 mill out of it, i'd consider they did a good job. 40% chance at phase 3 x 300 mill is120Mill ??. What is the true competitive landscape in a few years time? and is really a company maker?

https://www.moneycontrol.com/news/business/mergers-acquisitions/aurobindo-buys-7-oncology-injectable-drugs-in-300-million-deal-3405161.html
https://www.fiercepharma.com/pharma/30k-per-month-too-much-for-a-cancer-drug
https://finance.yahoo.com/news/spectrum-completes-deal-allos-therapeutics-213826282.html

I think Omnicar is the only really significant driver, but I did not hear any dates mentioned in the last investor presentation. I would be very, very annoyed if they slipped from what was being marketed late last year.

Using AML as a target seems more about proving the UIR concept works and works well. A positive outcome feels like it will build a very good platform. Then working on solids I would see as the real launch. I think something a bit more evolutionary like Omnicar could get investment much earlier. Hopefully a positive phase 1 trial update would change the companies fortunes quite a bit. Be interesting to see how the trial is done though. Seems like a lot of moving parts that would need to be tested in a very conservative manner and this would take time?

Anyway. Let's hope the word "shortly" evolves to mean 1-2 months and not 6-12 months.